Forskning og fagutvikling
- Kreftomsorg/-behandling
- Biomarkørdata (vev/blod)
- Virkelighetsdata (registerdata)
- Prognostiske modeller
- Kliniske utprøvingsstudier
- Kliniske observasjonsstudier
- Implementeringsstudier
- Registerstudier
- Kvantitativ forskning
Forskningsgrupper:
- Komplekse pasienttilstander, samhandling og erfaringer (COMPASS-e), LDH
- Forskergruppen for kolorektalkreft, Institutt for klinisk medisin, UiO
- Translational studies on solid tumours, Institutt for kreftforskning, OUS
- Seksjon for lymfom og indremedisin, Avdeling for kreftbehandling, OUS
- Nordisk biomoduleringsgruppe, internasjonalt nettverk
- Nordisk lymfomgruppe (NLG), internasjonalt nettverk
Forskningsprosjekter:
- Tykktarmskreft i Norge og betydning av kirurgi/strålebehandling ved spredning av tarmkreft. OUS
- Overlevelse og tilbakefall av tykk- og endetarmskreft. OUS
- Klinisk nytteverdi av analyser for sirkulerende tumor-DNA. OUS
- PI/SI i flere kliniske utprøvingsstudier for pasienter med lymfekreft. OUS
Undervisning
- Anatomi, fysiologi, biokjemi
- Generell sykdomslære
- Kreftsykdommer/onkologi
- Akuttonkologiske tilstander
- Smerter og smertebehandling
- Palliativ omsorg
- Internasjonal helse
- Kvantitative metoder
Bakgrunn
Utdanning:
- Ph.d. i medisin, Det medisinske fakultet, Universitetet i Oslo
- Global/internasjonal helse, Universitetet i København
- Cand.med., Det medisinske fakultet, Universitetet i Oslo
- Erasmusstipend, Karolinska Institutet, Stockholm
- B.Sc. i kjemi, Det matematisk-naturvitenskapelige fakultet, Universitetet i Oslo
- International baccalaureate, UWC Red Cross Nordic
Utvalgt arbeidserfaring:
- Overlege, Avdeling for kreftbehandling, Oslo universitetssykehus
- Høgskolelektor, Lovisenberg diakonale høgskole (deltid)
- Ekstern foreleser, Fakultet for helsefag, OsloMet – storbyuniversitetet (deltid)
- Lege i spesialisering, Avdeling for kreftbehandling, Oslo universitetssykehus
- Turnuslege, Universitetssykehuset Nord-Norge og Vega kommune
- Ingeniør, Institutt for kreftforskning, Oslo universitetssykehus (deltid)
- Sivilarbeider, Patologisk-anatomisk avdeling, Ullevål sykehus, Oslo universitetssykehus
Verv
- Fagekspert i metodevurderingsarbeid, RHF/SLV/Nye metoder
- Rådsmedlem, Norske leger mot atomvåpen
- Frivillig, International Network for Cancer Treatment and Research (2012)
Publiseringer
-
Incidence patterns of colorectal cancer in Norway 1993-2022 by age, site, and morphology
2024:
Mari Fjørtoft Ystgaard,Tor Åge Myklebust,Jørgen Smeby,Inger Kristin Larsen,Tormod Kyrre Guren,Elin Wenche Hegland Kure -
Initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-pola-mini-CHP and R-mini-CHOP
2023:
Mats Jerkeman,Sirpa Leppä,Julian Hamfjord,Peter Brown,Sara Ekberg,Andrés José María Ferreri -
Elevated protein expression levels of KRAS in Pancreatic Ductal Adenocarcinoma (PDAC) are associated with better prognosis.
2023:
Stina Margrethe Stålberg,Laxmi Silwat-Pandit,Julian Hamfjord,Daniel JH Nebdal,Janne Lehtiö,Bjørn Steen Skålhegg -
Identified palliative care needs at start of radiotherapy for painful bone metastases
2018:
Ellen Bjerkeset,Nina Kathrine Aass,Asta Bye,Julian Hamfjord,Marianne Jensen Hjermstad,Jon Håvard Loge -
Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis
2022:
Louise B. Callesen,Tana Takacova,Julian Hamfjord,Florian Würschmidt,Karl J. Oldhafer,Roland Brüning -
Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
2022:
Anand Khadse,Vilde Drageset Haakensen,Laxmi Silwal-Pandit,Julian Hamfjord,Patrick Micke,Johan Botling -
Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis
2022:
Louise B. Callesen,Julian Hamfjord,Anders K. Boysen,Niels Pallisgaard,Tormod Kyrre Guren,Elin Wenche Hegland Kure -
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
2021:
Julian Hamfjord,Tormod Kyrre Guren,Bengt Glimelius,Halfdan Sorbye,Per Pfeiffer,Olav Dajani -
Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades: A Norwegian Population-Based Study
2021:
Julian Hamfjord,Tor Åge Myklebust,Inger Kristin Larsen,Elin Wenche Hegland Kure,Bengt Glimelius,Tormod Kyrre Guren -
Using process indicators to monitor documentation of patient-centred variables in an integrated oncology and palliative care pathway—results from a cluster randomized trial
2021:
Marianne Jensen Hjermstad,Julian Hamfjord,Nina Kathrine Aass,Olav Dajani,Tonje Lundeby,Torunn Elin Wester -
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
2019:
Julian Hamfjord,Tormod Kyrre Guren,Olav Dajani,Julia Sidenius Johansen,Bengt Glimelius,Halfdan Sorbye -
Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy
2018:
Julian Hamfjord,Tormod Kyrre Guren,Olav Dajani,Bengt Glimelius,Halfdan Sorbye,Per Pfeiffer -
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
2016:
Janne Beathe Kjersem,Maria Thomsen,Tormod Kyrre Guren,Julian Hamfjord,G Carlsson,B. Gustavsson -
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
2016:
Vandana Sandhu,Inger Marie Bowitz Lothe,Knut Jørgen Labori,Martina Skrede,Julian Hamfjord,Astrid Marie Larsen -
Serum N-glycome characterization in patients with resectable periampullary adenocarcinoma
2015:
Julian Hamfjord,Radka Saldova,Henning Stockmann,Vandana Sandhu,Inger Marie Bowitz Lothe,Trond Buanes -
High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence
2015:
Vibeke Andersen,Lotte K. Vogel,Tine Iskov Kopp,Mona Sæbø,Annika W. Nonboe,Julian Hamfjord -
Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas
2015:
Vandana Sandhu,Inger Marie Bowitz Lothe,Knut Jørgen Labori,Ole Christian Lingjærde,Trond Buanes,Astrid Marie Dalsgaard -
Intestinal PTGS2 mRNA Levels, PTGS2 Gene Polymorphisms, and Colorectal Carcinogenesis
2014:
Lotte K. Vogel,Mona Sæbø,Helle Høyer,Tine Iskov Kopp,Ulla Vogel,Sine Godiksen -
Low ABCB1 Gene Expression Is an Early Event in Colorectal Carcinogenesis
2013:
Vibeke Andersen,Ulla Vogel,Sine Godiksen,Franz B. Frenzel,Mona Sæbø,Julian Hamfjord -
Molecular responses to toxicological stressors: Profiling microRNAs in wild Atlantic salmon (Salmo salar) exposed to acidic aluminum-rich water
2013:
Elin H. Kure,Mona Sæbø,Astrid Marie Dalsgaard,Julian Hamfjord,Sigurd Hytterød,Jan Heggenes -
Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing
2012:
Julian Hamfjord,Astrid Marie Stangeland,Timothy Hughes,Martina Skrede,Magne Kjell Tveit,Tone Ikdahl Andersen -
Let-7 miRNA-binding site polymorphism in the KRAS 3 ' UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
2012:
Janne Beathe Kjersem,Tone Ikdahl Andersen,Tormod Kyrre Guren,Eva Skovlund,Halfdan Sorbye,Julian Hamfjord -
Wobble-enhanced ARMS Method for Detection of KRAS and BRAF Mutations
2011:
Julian Hamfjord,Astrid Marie Stangeland,Martina Skrede,Magne Kjell Tveit,Tone Ikdahl Andersen,Elin H. Kure -
The multidrug resistance 1 (MDR1) gene polymorphism G-rs3789243-A is not associated with disease susceptibility in Norwegian patients with colorectal adenoma and colorectal cancer; a case control study
2009:
Vibeke Andersen,Lene Agerstjerne,Dorte Jensen,Mette Østergaard,Mona Sæbø,Julian Hamfjord -
Ufattelige lidelser : hvorfor atomvåpen må forbys
2016:
John Gunnar Mæland,Julian Hamfjord,Bjørn Hilt,Kirsten Kjelsberg Osen -
Hva er egentlig kreft?, Krafttak hos Kloppen
2017:
Julian Hamfjord -
KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem
2012:
Elin H. Kure,Julian Hamfjord,Astrid Marie Larsen,Magne Kjell Tveit,Tone Ikdahl